5-甲氧基-1,2,3,4-四氢萘-1-羧酸 | 80858-96-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 5-甲氧基-1,2,3,4-四氢萘-1-羧酸
• 英文名称: 5-methoxy-1,2,3,4-tetrahydronaphthalene-1-carboxylic acid
• 英文别名: 5-methoxy-1,2,3,4-tetrahydro-naphthalene-1-carboxylic acid；5-methoxy 1,2,3,4-tetrahydronaphthalene-1-carboxylic acid
• CAS: 80858-96-4
• 化学式: C₁₂H₁₄O₃
• 分子量: 206.241
• InChiKey: JQYDRTBHQBHLLB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-甲氧基-1,2,3,4-四氢萘-1-羧酸 在 lithium aluminium tetrahydride 、 草酰氯 、 二甲基十二/十四烷基叔胺 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 56.0h， 生成 1-[(1R)-5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl]-N-methylmethanamine
  参考文献：
  名称：

  Structure−Activity Studies for a Novel Series of N-(Arylethyl)-N-(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)-N-methylamines Possessing Dual 5-HT Uptake Inhibiting and α₂-Antagonistic Activities

  摘要：

  In search of an alpha(2)-antagonist/5-HT uptake inhibitor as a potential new class of antidepressant with a more rapid onset of action, compound 3 was prepared and observed to possess high affinity for the alpha(2)-receptor (K-i = 6.71 nM) and the 5-HT uptake site (20.6 nM). A series of tertiary amine analogs of 3 were synthesized and assayed for their affinity at both the alpha(2)-receptor and the 5-HT uptake site. The structure-activity relationship reveals that a variety of structural modifications to the arylethyl fragment are possible with retention of this dual activity. On the tetralin portion, 5-OMe substitution and the (R) stereochemistry at C-l are optimal with alternate substitutions producing compounds retaining high affinity for the alpha(2)-receptor but lacking affinity for the 5-HT uptake site. Data for several rigidified 5-O-alkyl analogs suggests that the favored orientation of the oxygen lone pairs may be away from the g-position of the tetralin.

  DOI：

  10.1021/jm960723m
• 作为产物：
  描述：

  5-甲氧基-3,4-二氢-2H-1-萘酮 在 盐酸 、 溶剂黄146 、 tin(ll) chloride 、 zinc(II) iodide 作用下， 反应 2.0h， 生成 5-甲氧基-1,2,3,4-四氢萘-1-羧酸
  参考文献：
  名称：

  1-环己基哌嗪的4-（四氢-1-基）-和4-（萘-1-基）烷基衍生物作为具有激动剂sigma2活性的sigma受体配体。

  摘要：

  与sigma（2）受体配体1-cyclohexyl-4- [3-（5-甲氧基-1,2,3,4-四氢萘-1-基）丙基]哌嗪有关的几种1-cyclohexylpiperazine衍生物（33，K（i合成＝ 0.34nM）并在放射性配体结合测定中测试，以尝试结构亲和关系研究。中间烷基链长度和四氢化萘核上的甲氧基位置是变化的。还制备了一些萘类似物。在几乎所有化合物的sigma（2）受体结合物中都发现了高亲和力，其中一些化合物在亚纳摩尔范围内显示出K（i）值，但是发现了低sigma（2）/ sigma（1）选择性。具有三个（32和43）或五个亚甲基（39和46）的中间烷基链的化合物显示出最高的sigma（2）亲和力。发现具有四亚甲基链的化合物具有相当高的sigma（1）受体亲和力。36（K（i）= 0.036 nM）和45（K（i）= 0.22 nM）显示出良好的sigma（1）/ sigma（2）

  DOI：

  10.1021/jm031026e

文献信息

• 1-Aryl-4-[(1-tetralinyl)alkyl]piperazines:  Alkylamido and Alkylamino Derivatives. Synthesis, 5-HT_1A Receptor Affinity, and Selectivity. 3
  作者：Roberto Perrone、Francesco Berardi、Marcello Leopoldo、Vincenzo Tortorella、Maria Gioia Fornaretto、Carla Caccia、Robert A. McArthur

  DOI：10.1021/jm960087s

  日期：1996.1.1

  or amido function is inserted into the intermediate chain linked to the alpha position of the tetralin nucleus. Unlike the buspirone analogues, for the amido derivatives studied in this paper, the terminal amide function of long-chain piperazines is not important for 5-HT1A receptor affinity binding, and its removal yields high-affinity 5-HT1A receptor agents.

  报告了N-4长链芳基哌嗪22-40的5-HT1A，5-HT2，D-1，D-2，α1和α2受体的合成和结合情况，其中氨基或酰胺基功能将“α”插入与四氢化萘核的α位连接的中间链中。与丁螺环酮类似物不同，对于本文研究的酰胺衍生物，长链哌嗪的末端酰胺功能对于5-HT1A受体亲和力结合并不重要，并且其去除会产生高亲和力的5-HT1A受体剂。
• NK1 and NK3 antagonists
  申请人：O'Neill T. Brian

  公开号：US20050256164A1

  公开（公告）日：2005-11-17

  The invention is to a compound exhibiting neurokinin inhibitory properties, a pharmaceutical composition comprising same and a method of treatment for neurokinin-mediated conditions.

  这项发明涉及一种具有神经激肽抑制性能的化合物，包括该化合物的药物组合物以及用于神经激肽介导疾病的治疗方法。
• [EN] TRITIUM RADIOLABELING OF [3H]-1-CYCLOHEXYL-4-[3-(5-METHOXY-1,2, 3,4,-TETRAHYDRONAPHTHALEN-1-YL)-N-PROPYL]PIPERAZINE ([3H]-PB28), AS A POTENT SIGMA-2 RECEPTOR LIGAND<br/>[FR] RADIOMARQUAGE AU TRITIUM DE [3H]-1-CYCLOHEXYL-4-[3-(5- MÉTHOXY-1,2,3,4-TÉTRAHYDRONAPHTALÈN-1-YL)-N-PROPYL]PIPÉRAZINE ([3H]-PB28), EN TANT QUE LIGAND EFFICACE DES RÉCEPTEURS SIGMA-2
  申请人：UNIV BARI

  公开号：WO2009104058A1

  公开（公告）日：2009-08-27

  The invention relates to a novel process for the radiolabeling with [3H] of the l-cyclohexyl-4- [3- (5- methoxy-1, 2,3,4, -tetrahydronaphthalen-1-yl) -n- propyl]piperazine (PB28) ligand of formula 1 and enantiomeric forms thereof, specific for the sigma-2 receptors. The invention further relates to the same radiolabeled ligand and to its use as a highly selective analytical instrument in the evaluation of the expression levels of said receptors in tissues, as selection tool of novel specific ligands, and as diagnostic agent in diagnostic kits.

  该发明涉及一种新型方法，用于对公式1中的l-环己基-4-[3-(5-甲氧基-1,2,3,4,-四氢萘基)-n-丙基]哌嗪（PB28）配体进行[3H]放射标记，以及其对映体形式，特异于sigma-2受体。该发明还涉及同一放射标记的配体及其用途，作为在组织中评估所述受体表达水平的高度选择性分析仪器，作为新型特异性配体的选择工具，并作为诊断试剂盒中的诊断试剂。
• Novel amide derivatives and medicinal use thereof ugs
  申请人：——

  公开号：US20040138223A1

  公开（公告）日：2004-07-15

  The present invention relates to an amide derivative of the formula (1), having a C5a receptor antagonistic action 1 wherein each symbol is as defined in the specification. The above-mentioned amide derivative, an optically active form thereof and a pharmaceutically acceptable salt thereof are promising as an agent for the treatment or prophylaxis of diseases or syndromes caused by inflammation caused by C5a [e.g., autoimmune diseases such as rheumatism, systemic lupus erythematosus and the like, sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease, allergic diseases such as asthma and the like, atherosclerosis, cardiac infarction, brain infarction, psoriasis, Alzheimer's disease and serious organ injury (e.g., pneumonia, nephritis, hepatitis and pancreatitis and the like) due to activation of leukocytes caused by ischemia reperfusion, trauma, burn, surgical invasion and the like]. Moreover, they are useful as a therapeutic or prophylactic agent for the infectious diseases caused by bacteria and virus that invade via a C5a receptor.

  本发明涉及一种式（1）的酰胺衍生物，具有C5a受体拮抗作用，其中每个符号如规范中所定义。上述酰胺衍生物及其光学活性形式和药学上可接受的盐被认为是治疗或预防因C5a引起的炎症引起的疾病或综合症的药物，如自身免疫性疾病，如风湿病，系统性红斑狼疮等，败血症，成人呼吸窘迫综合症，慢性阻塞性肺疾病，哮喘等过敏性疾病，动脉粥样硬化，心脏梗死，脑梗死，牛皮癣，老年痴呆症和严重器官损伤（如肺炎，肾炎，肝炎，胰腺炎等）由于缺血再灌注，创伤，烧伤，手术入侵等引起的白细胞激活。此外，它们对通过C5a受体侵入的细菌和病毒引起的传染病也有用作治疗或预防剂。
• Tertiary and secondary amines as alpha-2 antagonists and serotonin
  申请人：Abbott Laboratories

  公开号：US05288749A1

  公开（公告）日：1994-02-22

  The present invention provides tertiary and secondary amine compounds of the formula ##STR1## and the pharmaceutically acceptable salts thereof which are antagonists for alpha-2 adrenoreceptors and which inhibit serotonin (5-hydroxytryptamine, 5-HT) uptake.

  本发明提供了式子##STR1##的三级和二级胺化合物及其药学上可接受的盐，它们是α-2肾上腺素受体拮抗剂，并抑制血清素（5-羟色胺，5-HT）的摄取。